Quick Answer
MapLight Therapeutics, Inc. reported Diluted EPS of $18.56 per share (loss) for fiscal year 2025.
MapLight Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$18.56 | +82.4% |
| 2024 | -$105.38 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$37.18 | -48.2% | -48.2% |
| September 30, 2024 | -$25.08 | — | — |
- MapLight Therapeutics, Inc. showed an increase of +82.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, MapLight Therapeutics, Inc.’s diluted eps has grown by 82.4% (from $105.38 per share (loss) to $18.56 per share (loss)).
- The most recent figure is from MapLight Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: